Optimal Biologic Drugs for the Treatment of Ankylosing Spondylitis: Results from a Network Meta-Analysis and Network Metaregression

BACKGROUND: Ankylosing spondylitis (AS) is a common immune-related systemic chronic inflammatory osteoarthropathy. Previous studies have proven that biologic agents, including IL-17A inhibitors (IL17Ai), TNF-α inhibitor FC fusion protein (TNFiFCP), or fully human monoclonal antibody (TNFiNMA) and JA...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Ziqin, Guo, Jia, Li, Qiangxiang, Li, Yajia, Wu, Jianhuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279076/
https://www.ncbi.nlm.nih.gov/pubmed/35845959
http://dx.doi.org/10.1155/2022/8316106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279076/
https://www.ncbi.nlm.nih.gov/pubmed/35845959
http://dx.doi.org/10.1155/2022/8316106

Ejemplares similares